Reuters logo
REFILE-BRIEF-U.S. FDA Grants Breakthrough Therapy Designation for Genentech's Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII Inhibitors
September 4, 2015 / 5:16 AM / 2 years ago

REFILE-BRIEF-U.S. FDA Grants Breakthrough Therapy Designation for Genentech's Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII Inhibitors

(Corrects source spelling to Genentech from Genetech)

Sept 4 (Reuters) - Sept 4 (Reuters) - Genentech: * U.S. FDA grants breakthrough therapy designation for Genentech’s investigational medicine ACE910 for people with Hemophilia A with factor VIII inhibitors * Genentech says is preparing to initiate a phase III trial of ace910 in patients with Hemophilia a with factor VIII inhibitors by the end of 2015 * Genentech says to initiate phase III trial in patients without inhibitors in 2016 * Source text for Eikon * Further company coverage

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below